Clinical determinants of migraine preventive treatment: Contribution of SMILE, an observational survey of primary care migraine management in France

Cephalalgia

Volumn 30, Issue 10, 2010, Pages 1207-1213

  Valade, D ^a   Lanteri Minet M ^b   Radat, F ^c   Mekies, C ^d   Lucas, C ^e   Vives E ^d   Joubert, J M ^d   Geraud G ^f  

^a Lariboisiere Hospital   (France)

^b Pasteur University Hospital   (France)

^c Pellegrin University Hospital   (France)

^d Private Neurology Practice ^*  (France)

^e Salengro Hospital   (France)

^f CHU RANGUEIL   (France)

Author keywords

Eligibility; Migraine; Observational study; Preventive treatment; Primary care

Indexed keywords

ACETYLSALICYLIC ACID; ERGOTAMINE DERIVATIVE; METOCLOPRAMIDE; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; TRIPTAN DERIVATIVE; ANALGESIC AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FRANCE; GENERAL PRACTITIONER; HEADACHE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; MIGRAINE; NEUROLOGIST; OBSERVATIONAL STUDY; PATIENT SATISFACTION; PRESCRIPTION; PREVENTIVE MEDICINE; PRIMARY MEDICAL CARE; SMILE STUDY; ANXIETY; CLINICAL PRACTICE; MIDDLE AGED; NEUROLOGY; OBSERVATION; PRIMARY HEALTH CARE; PSYCHOLOGICAL ASPECT; QUESTIONNAIRE; STATISTICS;

ANALGESICS; ANXIETY; FEMALE; FRANCE; GENERAL PRACTITIONERS; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; NEUROLOGY; OBSERVATION; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS, PRIMARY CARE; PRIMARY HEALTH CARE; QUESTIONNAIRES;

EID: 79952113078     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1177/0333102409355661     Document Type: Article

References (19)

1. Rozen TD. Migraine prevention: what patients want from medication and their physicians (a headache specialty clinic perspective). Headache 2006; 46: 750-753.
2. Silberstein SD, Goadsby PJ. Migraine: preventive treat-ment. Cephalalgia 2002; 22: 491-512.
3. Stewart WF, Shechter A, Rasmussen RK. Migraine prev-alence: a review of population-based studies. Neurology 1994; 44(Suppl 4): 17-23.
4. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001; 41: 646-657. (Pubitemid 32777747)
5. Lucas C, Chaffaut C, Artaz MA, Lanteri-Minet M. FRAMIG 2000: medical and therapeutic manage-ment of migraine in France. Cephalalgia 2005; 25: 267-279. (Pubitemid 40445811)
6. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF, on behalf of the AMPP Advisory Group. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007; 68: 343-349. (Pubitemid 46184209)
7. Rasmussen BK. Epidemiology of headache. Cephalalgia 1995; 15: 45-68.
8. US Headache Consortium. Evidence-basedguidelines for migraine headache in the primary care setting: pharmaco-logical management for prevention of migraine. http://www.aan.com/professionals/practice/pdfs/gl0090.pdf (2000, consulted October 2009).
9. World Health Organization. Lifting the burden: the global campaign to reduce the burden of headache world-wide. J Headache Pain 2007; 8: S110.
10. Wissmann A, Feuersenger A, Gendolla A, et al. Devel-opment of a screening tool for migraine prophylaxis. Schmerz 2007; 21(5): 430-438. (Pubitemid 350049403)
11. International Headache Society. The International Clas-sification of Headache Disorders. 2nd ed. Cephalalgia 2004; 24(Suppl 1): 8-152.
12. Geraud G, Lanteri-Minet M, Lucas C, Valade D, on behalf of the French Society for the Study of Migraine Headache (SFEMC). French guidelines for the diagnosis and management of migraine in adults and children. Clin Ther 2004; 26: 1305-1318. (Pubitemid 39445352)
13. D'Amico D, Lanteri-Minet M. Migraine preventive ther-apy: selection of appropriate patients and general princi-ples of management. Expert Rev Neurother 2006; 6: 1147-1157. (Pubitemid 44231973)
14. Lanteri-Minet M, Radat F, Chautard MH, Lucas C. Anxi-ety and depression associated with migraine: influence on migraine subjects' disability and quality of life, and acute migraine management. Pain 2005; 118: 319-326. (Pubitemid 41752989)
15. Lanteri-Minet M, Valade D, Geraud G, Chautard MH, Lucas C. Migraine and probable migraine: results of FRAMIG 3, a French nationwide survey carried out according to the 2004 IHS classification. Cephalalgia 2005; 25: 1146-1158. (Pubitemid 41774861)
16. Dodick D. Patient perceptions and treatment preferences in migraine management. CNS Drugs 2002; 16(Suppl 1): 19-24.
17. Massiou H. Migraine medication attributes are impor-tant for patient compliance. Drugs Today 2003; 39(Suppl D): 25-29. (Pubitemid 38280251)
18. D'Amico D. Treatment strategies in migraine patients. Neurol Sci 2004; 25(Suppl3): 242-243.
19. Peres MF, Silberstein S, Moreira F, et al. Patients' pref-erence for migraine preventive therapy. Headache 2007; 47: 540-545. (Pubitemid 46625262)